- Home
- NX vs NRIX Comparison
NX vs NRIX Comparison
Compare NX & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NX
- NRIX
- Stock Information
- Founded
- NX 1927
- NRIX 2009
- Country
- NX United States
- NRIX United States
- Employees
- NX N/A
- NRIX N/A
- Industry
- NX Metal Fabrications
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- NX Industrials
- NRIX Health Care
- Exchange
- NX Nasdaq
- NRIX Nasdaq
- Market Cap
- NX 1.1B
- NRIX 1.1B
- IPO Year
- NX N/A
- NRIX 2020
- Fundamental
- Price
- NX $18.61
- NRIX $11.88
- Analyst Decision
- NX Strong Buy
- NRIX Strong Buy
- Analyst Count
- NX 1
- NRIX 17
- Target Price
- NX $38.00
- NRIX $30.82
- AVG Volume (30 Days)
- NX 592.3K
- NRIX 879.4K
- Earning Date
- NX 03-10-2025
- NRIX 04-14-2025
- Dividend Yield
- NX 1.72%
- NRIX N/A
- EPS Growth
- NX N/A
- NRIX N/A
- EPS
- NX 0.29
- NRIX N/A
- Revenue
- NX $1,438,751,000.00
- NRIX $54,549,000.00
- Revenue This Year
- NX $49.00
- NRIX N/A
- Revenue Next Year
- NX $2.89
- NRIX $3.20
- P/E Ratio
- NX $64.10
- NRIX N/A
- Revenue Growth
- NX 29.87
- NRIX N/A
- 52 Week Low
- NX $18.14
- NRIX $11.38
- 52 Week High
- NX $38.98
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- NX 37.33
- NRIX 29.28
- Support Level
- NX $19.53
- NRIX $12.20
- Resistance Level
- NX $20.47
- NRIX $13.10
- Average True Range (ATR)
- NX 0.69
- NRIX 0.77
- MACD
- NX 0.01
- NRIX -0.01
- Stochastic Oscillator
- NX 16.73
- NRIX 14.33
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.